Sareum to Release Interim Results and Host Live Investor Presentation

Sareum Holdings ( (GB:SAR) ) has issued an update.

Sareum Holdings said it will publish its unaudited interim financial results for the six months to 31 December 2025 on 12 March 2026. The update will give investors a mid-year view on the progress and financial health of the company as it advances its kinase inhibitor pipeline.

Alongside the figures, Sareum will host a live online investor presentation on the same day via the Investor Meet Company platform, open to existing and prospective shareholders. The event, which will be followed by the publication of the presentation on the company’s website, underscores Sareum’s efforts to broaden engagement and transparency with its retail and institutional investor base.

The most recent analyst rating on (GB:SAR) stock is a Hold with a £15.50 price target. To see the full list of analyst forecasts on Sareum Holdings stock, see the GB:SAR Stock Forecast page.

Spark’s Take on GB:SAR Stock

According to Spark, TipRanks’ AI Analyst, GB:SAR is a Neutral.

The score is primarily constrained by weak financial performance (pre-revenue with persistent losses and continued cash burn) and bearish technical signals (below key moving averages with negative MACD). Valuation provides limited support because the company is loss-making and no dividend yield is available.

To see Spark’s full report on GB:SAR stock, click here.

More about Sareum Holdings

Sareum Holdings plc is a clinical-stage biotechnology company focused on developing next-generation kinase inhibitors targeting autoimmune diseases and cancer. Listed on AIM in London under the ticker SAR, the company operates in the biopharmaceutical sector, aiming to advance innovative small-molecule therapies for serious inflammatory and oncology indications.

Average Trading Volume: 238,985

Technical Sentiment Signal: Strong Sell

Current Market Cap: £20.71M

For detailed information about SAR stock, go to TipRanks’ Stock Analysis page.